Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT05760755
Other study ID # P-2020-246
Secondary ID H-22032044
Status Enrolling by invitation
Phase N/A
First received
Last updated
Start date February 1, 2023
Est. completion date May 31, 2024

Study information

Verified date March 2023
Source Rigshospitalet, Denmark
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This pilot study investigates the acceptability and feasibility of 'Stick Together', a self-guided online intervention, for younger women with breast cancer and their cohabiting partners.


Description:

This one-arm feasibility study pilots the 'Stick Together' intervention among 20 women newly diagnosed with breast cancer at age 25-49 and their cohabiting partners. The intervention aims to strengthen couples' positive dyadic coping and communication, as well as participants mental health and quality of life, as well as quality of life of underage children.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 50
Est. completion date May 31, 2024
Est. primary completion date May 31, 2024
Accepts healthy volunteers No
Gender Female
Age group 25 Years to 49 Years
Eligibility Inclusion Criteria (patients): - women newly diagnosed with first primary breast cancer, treated with curative intent at Department of breast surgery, Gentofte Hospital - living with a romantic partner Inclusion Criteria (partners): - living in romantic partnership with a patient eligible for the intervention Exclusion Criteria (both patients and partners): - severe relationship difficulties or current couples counselling - severe, untreated mental illness in one or both partners - capable of participating (mastery of Danish language, available smartphone, tablet or other device, no cognitive impairment)

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Stick Together
The intervention consists of 12 online modules, completed flexibly during and immediately after primary cancer treatment. The intervention contains interviews with other couples, psychoeducational information, and interactive exercises on themes such as dyadic coping and communication, being diagnosed at a young age, fertility and children, and life after treatment.

Locations

Country Name City State
Denmark Department of breast surgery, Gentofte Hospital Gentofte

Sponsors (6)

Lead Sponsor Collaborator
Rigshospitalet, Denmark Danish Cancer Society, Danish Committee for Health Education, Sygekassernes Helsefond, TrygFonden, Denmark, University Hospital, Gentofte, Copenhagen

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Participation (Acceptability 1) Percentage of eligible participants consenting to participate baseline
Primary Participants satisfaction (Acceptability 2) Percentage of participants satisfied with the intervention Post-intervention follow-up (7-9 months post diagnosis)
Primary Completion (Feasibility) Percentage of participants completing the intervention (65% completion) Post-intervention (7-9 months post diagnosis)
Secondary Change from baseline to post-intervention in supportive dyadic coping Score on supportive dyadic coping (min 5, max 25), as measured by the Dyadic coping inventory subscale. Higher scores indicate better outcome. Baseline, after intervention completion (average 8 months after diagnosis)
Secondary Change from baseline to post-intervention in delegated dyadic coping Score on delegated dyadic coping (min 2, max 10), as measured by the Dyadic coping inventory subscale. Higher scores indicate better outcome. Baseline, after intervention completion (average 8 months after diagnosis)
Secondary Change from baseline to post-intervention in negative dyadic coping Score on negative dyadic coping (min 4, max 20), as measured by the Dyadic coping inventory subscale. Higher scores indicate worse outcome. Baseline, after intervention completion (average 8 months after diagnosis)
Secondary Change from baseline to post-intervention in stress communication Score on stress communication (min 4, max 20), as measured by the Dyadic coping inventory subscale. Higher scores indicate better outcome. Baseline, after intervention completion (average 8 months after diagnosis)
Secondary Change from baseline to post-intervention in satisfaction with dyadic coping Score on satisfaction with dyadic coping (min 2, max 10), as measured by the Dyadic coping inventory subscale. Higher scores indicate better outcome. Baseline, after intervention completion (average 8 months after diagnosis)
Secondary Change from baseline to post-intervention in joint dyadic coping Score on joint dyadic coping (min 5, max 25), as measured by the Dyadic coping inventory subscale. Higher scores indicate better outcome. Baseline, after intervention completion (average 8 months after diagnosis)
Secondary Change from baseline to post-intervention in perceived stress Score on perceived stress (min 0, max 16), as measured by the Perceived Stress Scale. Higher scores indicate worse outcome. Baseline, after intervention completion (average 8 months after diagnosis)
Secondary Change from baseline to post-intervention in anxiety Score on anxiety symptoms (min 0, max 21), as measured by the Generalized anxiety scale-7. Higher scores indicate worse outcome. Baseline, after intervention completion (average 8 months after diagnosis)
Secondary Change from baseline to post-intervention in depression Score on depression symptoms (min 0, max 27), as measured by the Patient Health Questionnaire-9. Higher scores indicate worse outcome. Baseline, after intervention completion (average 8 months after diagnosis)
Secondary Change from baseline to post-intervention in protective buffering Score on protective buffering (min 8, max 40), as measured by the Ways of Giving Support-questionnaire subscale. Higher scores indicate worse outcome. Baseline, after intervention completion (average 8 months after diagnosis)
Secondary Change from baseline to post-intervention in active engagement Score on active engagement (min 5, max 25), as measured by the Ways of Giving Support-questionnaire subscale. Higher scores indicate better outcome. Baseline, after intervention completion (average 8 months after diagnosis)
Secondary Change from baseline to post-intervention in overprotection Score on overprotection (min 6, max 30), as measured by the Ways of Giving Support-questionnaire subscale. Higher scores indicate worse outcome. Baseline, after intervention completion (average 8 months after diagnosis)
Secondary Change from baseline to post-intervention in psychological quality of life Score on psychological quality of life (min 0, max 100), as measured by the World Health Organization Quality of Life Brief Version subscale (WHOQOL-BREF). Higher scores indicate better outcome. Baseline, after intervention completion (average 8 months after diagnosis)
Secondary Change from baseline to post-intervention in physical quality of life Score on physical quality of life (min 0, max 100), as measured by the World Health Organization Quality of Life Brief Version scubscale (WHOQOL-BREF). Higher scores indicate better outcome. Baseline, after intervention completion (average 8 months after diagnosis)
Secondary Change from baseline to post-intervention in social quality of life Score on social quality of life (min 0, max 100), as measured by the World Health Organization Quality of Life Brief Version subscale (WHOQOL-BREF). Higher scores indicate better outcome. Baseline, after intervention completion (average 8 months after diagnosis)
Secondary Change from baseline to post-intervention in children's quality of life Total mean score on quality of life (min 0, max 100), as measured by the Pediatric Quality of LIfe inventory (PEDSQL). Higher scores indicate better outcome. Baseline, after intervention completion (average 8 months after diagnosis)
See also
  Status Clinical Trial Phase
Completed NCT03080623 - Ultrasound-based Diagnostic Model for Differentiating Malignant Breast Lesion From Benign Lesion
Completed NCT05527769 - Pain and Functional Recovery After Mastectomy and IBR by Implant: Prepectoral Versus Subpectoral Technique
Completed NCT06376578 - Exercise Interventions for Improving Health in Breast Cancer Survivors N/A
Completed NCT03004534 - A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide Early Phase 1
Recruiting NCT05020574 - Microbiome and Association With Implant Infections Phase 2
Active, not recruiting NCT06277141 - The Vitality Mammography Messaging Study N/A
Completed NCT03555227 - USG PECS vs LIA for Breast Cancer Surgery N/A
Completed NCT03270111 - High Physical Activity During a Weight Loss Intervention for Breast Cancer Survivors and High Risk Women N/A
Active, not recruiting NCT03917082 - Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer Phase 2
Recruiting NCT05561842 - Tablet-based Mobile Health Ultrasound for Point-of-care Breast Cancer Diagnosis in Nigeria (Mobile Health: Technology and Outcomes in Low and Middle-Income Countries)
Completed NCT04554056 - Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF Phase 2/Phase 3
Not yet recruiting NCT06351332 - A Phase I/II Single-arm Trial of Azenosertib (ZN-c3) Combined With Carboplatin and Pembrolizumab in Patients With Metastatic Triple-negative Breast Cancer (ZAP-IT) Phase 1/Phase 2
Active, not recruiting NCT03127995 - Hypofractionated vs Standard Radiotherapy in Breast Cancer With an Indication for Regional Lymph Node Irradiation About Lymphedema Occurrence N/A
Active, not recruiting NCT02237469 - Prone Breast Radiotherapy Treatment Planning Observational Study
Completed NCT01204125 - Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients Phase 2
Recruiting NCT04565054 - Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC Phase 3
Not yet recruiting NCT06412133 - Conversations in Light and Shadow: Assessing Phototherapy's Impact on Breast Cancer Patients N/A
Recruiting NCT03956641 - Evolution of the Physical Condition in Treated Cancer Patients N/A
Recruiting NCT06087120 - Investigate the Prognostic and Predictive Value of ctDNA During Neoadjuvant Chemotherapy for Breast Cancer.
Recruiting NCT06058936 - Exercises Using Virtual Reality on Cancer Patients N/A